Nevertheless, as the disease progresses, the frequency of CD226+ cells among EM T cells reduces in CLL patients, and a significant reduction in the EFF subset was observed compared to HCs and earlier stages of the disease (Fig. 2I–K). This evidence concerns the gene CD226 and B-cell chronic lymphocytic leukemia.